LETITIA LINCECUM: Open Payments
NPI 1346655289 · ALEXANDRIA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$720 in 20 payments from 8 companies in 2025. Trend: 2023 $301 · 2024 $534 · 2025 $720
Food & beverage: $720
| Company | Payments | Amount |
|---|---|---|
| Ardelyx, Inc. | 4 | $256 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $153 |
| Janssen Biotech, Inc. | 2 | $146 |
| ABBVIE INC. | 6 | $101 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $17 |
| Amgen Inc. | 1 | $17 |
| Abbott Laboratories | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
Products named: IBSRELA, XIFAXAN, TREMFYA, UBRELVY, CAPLYTA, OTEZLA, VRAYLAR, FREESTYLE LIBRE 3.
Industry payments across LA — which companies pay providers there.
